Navigation Links
First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
Date:12/22/2011

LOS ANGELES, Dec. 22, 2011 /PRNewswire/ -- Thanks to continued generous support from mesothelioma victims, their families, friends, and advocates, the Pacific Meso Center (PMC) announces the opening of its new state-of-the-art mesothelioma research laboratory dedicated solely to the discovery of new treatments for malignant pleural mesothelioma (MPM), a cancer of the chest lining caused by asbestos exposure.

Pacific Meso Center (PMC) is a division of the Pacific Heart, Lung & Blood Institute (PHLBI), a 501(c)(3) non-profit medical research organization established in 2002, and is focused on both the treatment and prevention of MPM.

As the first of its kind in the world, the research lab was established to lead a focused and collaborative mesothelioma research effort that is independent of the limitations often imposed by academic as well as private medical institutions. The lab will focus not only on the development of novel treatments for mesothelioma but also on its prevention.

A team of physicians and scientists will be involved, including one of the foremost experts in the field of mesothelioma research and treatment, Robert B. Cameron, M.D. Dr. Cameron is a cardiothoracic surgeon and surgical oncologist, the director of the UCLA Comprehensive Mesothelioma Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans' Administration Medical Center, and a long-time proponent of lung-sparing surgery for malignant pleural mesothelioma. He recently chaired the First International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica, CA.

Others involved in the research program include Warren Grundfest, M.D., Sherven Sharma, PhD, Saroj Basak, PhD, Dongmei Hou, PhD, Marko Kostic, MSc, as well as others. These include a rapidly expanding group of international collaborators who share Dr. Cameron's vision of an open collaborative effort both in basic and translational science to facilitate the rapid development of the most promising therapies from the lab to the bedside for mesothelioma victims everywhere.

Important initial projects include:

  • The establishment of an international tissue bank.
  • The development of intraoperative cryotherapy; freezing suggests that cancer cells remaining after resections may be killed using cold gases to freeze the surface lining of the chest cavity.
  • Initiation of a stromal cell modification project; the interaction between stromal cells and tumor cells is known to play a major role in cancer growth and progression. 
  • The identification of a predictive model for drug prevention of malignant pleural mesothelioma.

Dr. Cameron commented, "Although I have operated on hundreds of patients suffering from malignant pleural mesothelioma and have reviewed all the recent and past mesothelioma research, I have never seen such enthusiasm and genuine hope that this laboratory embodies and holds for all mesothelioma victims." Dr. Cameron went on to say that, "I believe these exciting projects quickly will give us valuable information, some of which I anticipate will be covered in our 2nd International Symposium scheduled for May 12th, 2012 in Santa Monica, California."

For further information, please contact:

Clare Cameron
310-478-4678
ccameron@phlbi.org 
http://www.pacificmesocenter.org or http://www.phlbi.org 

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Pacific Meso Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
2. Amgen Announces 2012 First Quarter Dividend
3. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
4. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
5. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
8. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
10. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Holly Springs, North Carolina (PRWEB) , ... May ... ... comprehensive process automation and building management solutions and services based in Aurora, Ohio, ... a decade of established business in the Research Triangle Park area, this new ...
(Date:5/20/2016)... ... 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural ... to treat the disease. Surviving Mesothelioma has just posted an article on the new ... institutions based their mesothelioma study on the fact the Manumycin A, a derivative of ...
(Date:5/19/2016)... ... 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, a ... Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 years ... preclinical and clinical safety programs. “We’ve seen significant demand for, and we are ...
(Date:5/18/2016)... The Biotech industry continues to face ... there are no opportunities ahead. Today, ActiveWallSt.com has on its ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ), ... (NASDAQ: OPHT ). Sign up now to receive ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained 0.68%, ...
Breaking Biology Technology:
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
Breaking Biology News(10 mins):